Resistin Impairs Insulin-Evoked Vasodilation
Resistin Impairs Insulin-Evoked Vasodilation Maria Teresa Gentile 1 , Carmine Vecchione 1 , Gennaro Marino 1 , Alessandra Aretini 1 , Alba Di Pardo 1 , Giovanna Antenucci 1 , Angelo Maffei 1 , Giuseppe Cifelli 1 , Luca Iorio 1 , Alessandro Landolfi 1 , Giacomo Frati 2 and Giuseppe Lembo 1 , 2 1 Depa...
Saved in:
Published in | Diabetes (New York, N.Y.) Vol. 57; no. 3; pp. 577 - 583 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Alexandria, VA
American Diabetes Association
01.03.2008
|
Subjects | |
Online Access | Get full text |
ISSN | 0012-1797 1939-327X 1939-327X |
DOI | 10.2337/db07-0557 |
Cover
Loading…
Abstract | Resistin Impairs Insulin-Evoked Vasodilation
Maria Teresa Gentile 1 ,
Carmine Vecchione 1 ,
Gennaro Marino 1 ,
Alessandra Aretini 1 ,
Alba Di Pardo 1 ,
Giovanna Antenucci 1 ,
Angelo Maffei 1 ,
Giuseppe Cifelli 1 ,
Luca Iorio 1 ,
Alessandro Landolfi 1 ,
Giacomo Frati 2 and
Giuseppe Lembo 1 , 2
1 Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy
2 Department of Experimental Medicine and Pathology, La Sapienza University of Rome, Rome, Italy
Address correspondence and reprint requests to Giuseppe Lembo, MD, PhD, La Sapienza University of Rome, c/o Neuromed Institute,
Località Camerelle, 86077 Pozzilli (IS), Italy. E-mail: lembo{at}neuromed.it
Abstract
OBJECTIVE —Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin,
a recently discovered hormone markedly increased in obesity.
RESEARCH DESIGN AND METHODS —We performed our analysis on aortic and mesenteric segments from young and old C57BL/6 mice and on cultured endothelial cells.
Resistin-induced vascular effect was evaluated in vitro and in vivo. Molecular analyses were performed by immunoprecipitation
and Western blotting.
RESULTS —Recombinant murine resistin did not induce changes in either basal vascular tone or phenylephrine-induced vascular contraction.
In contrast, both in vivo and in vitro administration of resistin significantly impaired dose-dependent insulin-evoked vasodilation
by reducing endothelial nitric oxide synthase (eNOS) enzymatic activity. This effect of resistin was selective for insulin
vascular action, since vasodilatation induced by increasing doses of acetylcholine or nitroglycerin was not influenced by
the hormone. Molecular analysis of endothelial cells further detailed resistin-induced vascular resistance by showing impairment
of insulin-evoked AKT and eNOS phosphorylations after exposure to resistin. Even this latter abnormality is selective of insulin
signaling since AKT/eNOS phosphorylations are normally activated during acetylcholine stimulation. More important, the resistin-induced
endothelial dysfunction depends on resistin's ability to alter insulin receptor substrate (IRS)-1 tyrosine/serine phosphorylation
and its consequent interaction with phosphatidylinositol 3-kinase.
CONCLUSIONS —Our results demonstrate that resistin is able to induce a selective vascular insulin resistance-impairing endothelial IRS-1
signaling pathway that leads to eNOS activation and vasodilation.
eNOS, endothelial nitric oxide synthase
IRS, insulin receptor substrate
l -NAME, l - N G -nitro- l -arginine methyl ester
PI, phosphatidylinositol
Footnotes
Published ahead of print at http://diabetes.diabetesjournals.org on 7 December 2007. DOI: 10.2337/db07-0557.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore
be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received April 24, 2007.
Accepted November 27, 2007.
DIABETES |
---|---|
AbstractList | Resistin Impairs Insulin-Evoked Vasodilation
Maria Teresa Gentile 1 ,
Carmine Vecchione 1 ,
Gennaro Marino 1 ,
Alessandra Aretini 1 ,
Alba Di Pardo 1 ,
Giovanna Antenucci 1 ,
Angelo Maffei 1 ,
Giuseppe Cifelli 1 ,
Luca Iorio 1 ,
Alessandro Landolfi 1 ,
Giacomo Frati 2 and
Giuseppe Lembo 1 , 2
1 Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy
2 Department of Experimental Medicine and Pathology, La Sapienza University of Rome, Rome, Italy
Address correspondence and reprint requests to Giuseppe Lembo, MD, PhD, La Sapienza University of Rome, c/o Neuromed Institute,
Località Camerelle, 86077 Pozzilli (IS), Italy. E-mail: lembo{at}neuromed.it
Abstract
OBJECTIVE —Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin,
a recently discovered hormone markedly increased in obesity.
RESEARCH DESIGN AND METHODS —We performed our analysis on aortic and mesenteric segments from young and old C57BL/6 mice and on cultured endothelial cells.
Resistin-induced vascular effect was evaluated in vitro and in vivo. Molecular analyses were performed by immunoprecipitation
and Western blotting.
RESULTS —Recombinant murine resistin did not induce changes in either basal vascular tone or phenylephrine-induced vascular contraction.
In contrast, both in vivo and in vitro administration of resistin significantly impaired dose-dependent insulin-evoked vasodilation
by reducing endothelial nitric oxide synthase (eNOS) enzymatic activity. This effect of resistin was selective for insulin
vascular action, since vasodilatation induced by increasing doses of acetylcholine or nitroglycerin was not influenced by
the hormone. Molecular analysis of endothelial cells further detailed resistin-induced vascular resistance by showing impairment
of insulin-evoked AKT and eNOS phosphorylations after exposure to resistin. Even this latter abnormality is selective of insulin
signaling since AKT/eNOS phosphorylations are normally activated during acetylcholine stimulation. More important, the resistin-induced
endothelial dysfunction depends on resistin's ability to alter insulin receptor substrate (IRS)-1 tyrosine/serine phosphorylation
and its consequent interaction with phosphatidylinositol 3-kinase.
CONCLUSIONS —Our results demonstrate that resistin is able to induce a selective vascular insulin resistance-impairing endothelial IRS-1
signaling pathway that leads to eNOS activation and vasodilation.
eNOS, endothelial nitric oxide synthase
IRS, insulin receptor substrate
l -NAME, l - N G -nitro- l -arginine methyl ester
PI, phosphatidylinositol
Footnotes
Published ahead of print at http://diabetes.diabetesjournals.org on 7 December 2007. DOI: 10.2337/db07-0557.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore
be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received April 24, 2007.
Accepted November 27, 2007.
DIABETES OBJECTIVE—Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently discovered hormone markedly increased in obesity. RESEARCH DESIGN AND METHODS—We performed our analysis on aortic and mesenteric segments from young and old C57BL/6 mice and on cultured endothelial cells. Resistin-induced vascular effect was evaluated in vitro and in vivo. Molecular analyses were performed by immunoprecipitation and Western blotting. RESULTS—Recombinant murine resistin did not induce changes in either basal vascular tone or phenylephrine-induced vascular contraction. In contrast, both in vivo and in vitro administration of resistin significantly impaired dose-dependent insulin-evoked vasodilation by reducing endothelial nitric oxide synthase (eNOS) enzymatic activity. This effect of resistin was selective for insulin vascular action, since vasodilatation induced by increasing doses of acetylcholine or nitroglycerin was not influenced by the hormone. Molecular analysis of endothelial cells further detailed resistin-induced vascular resistance by showing impairment of insulin-evoked AKT and eNOS phosphorylations after exposure to resistin. Even this latter abnormality is selective of insulin signaling since AKT/eNOS phosphorylations are normally activated during acetylcholine stimulation. More important, the resistin-induced endothelial dysfunction depends on resistin's ability to alter insulin receptor substrate (IRS)-1 tyrosine/serine phosphorylation and its consequent interaction with phosphatidylinositol 3-kinase. CONCLUSIONS—Our results demonstrate that resistin is able to induce a selective vascular insulin resistance-impairing endothelial IRS-1 signaling pathway that leads to eNOS activation and vasodilation. Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently discovered hormone markedly increased in obesity. We performed our analysis on aortic and mesenteric segments from young and old C57BL/6 mice and on cultured endothelial cells. Resistin-induced vascular effect was evaluated in vitro and in vivo. Molecular analyses were performed by immunoprecipitation and Western blotting. Recombinant murine resistin did not induce changes in either basal vascular tone or phenylephrine-induced vascular contraction. In contrast, both in vivo and in vitro administration of resistin significantly impaired dose-dependent insulin-evoked vasodilation by reducing endothelial nitric oxide synthase (eNOS) enzymatic activity. This effect of resistin was selective for insulin vascular action, since vasodilatation induced by increasing doses of acetylcholine or nitroglycerin was not influenced by the hormone. Molecular analysis of endothelial cells further detailed resistin-induced vascular resistance by showing impairment of insulin-evoked AKT and eNOS phosphorylations after exposure to resistin. Even this latter abnormality is selective of insulin signaling since AKT/eNOS phosphorylations are normally activated during acetylcholine stimulation. More important, the resistin-induced endothelial dysfunction depends on resistin's ability to alter insulin receptor substrate (IRS)-1 tyrosine/serine phosphorylation and its consequent interaction with phosphatidylinositol 3-kinase. Our results demonstrate that resistin is able to induce a selective vascular insulin resistance-impairing endothelial IRS-1 signaling pathway that leads to eNOS activation and vasodilation. Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently discovered hormone markedly increased in obesity. We performed our analysis on aortic and mesenteric segments from young and old C57BL/6 mice and on cultured endothelial cells. Resistin-induced vascular effect was evaluated in vitro and in vivo. Molecular analyses were performed by immunoprecipitation and Western blotting. Recombinant murine resistin did not induce changes in either basal vascular tone or phenylephrine-induced vascular contraction. In contrast, both in vivo and in vitro administration of resistin significantly impaired dose-dependent insulin-evoked vasodilation by reducing endothelial nitric oxide synthase (eNOS) enzymatic activity. This effect of resistin was selective for insulin vascular action, since vasodilatation induced by increasing doses of acetylcholine or nitroglycerin was not influenced by the hormone. Molecular analysis of endothelial cells further detailed resistin-induced vascular resistance by showing impairment of insulin-evoked AKT and eNOS phosphorylations after exposure to resistin. Even this latter abnormality is selective of insulin signaling since AKT/eNOS phosphorylations are normally activated during acetylcholine stimulation. More important, the resistin-induced endothelial dysfunction depends on resistin's ability to alter insulin receptor substrate (IRS)-1 tyrosine/serine phosphorylation and its consequent interaction with phosphatidylinositol 3-kinase. Our results demonstrate that resistin is able to induce a selective vascular insulin resistance-impairing endothelial IRS-1 signaling pathway that leads to eNOS activation and vasodilation. Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently discovered hormone markedly increased in obesity.OBJECTIVESince vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently discovered hormone markedly increased in obesity.We performed our analysis on aortic and mesenteric segments from young and old C57BL/6 mice and on cultured endothelial cells. Resistin-induced vascular effect was evaluated in vitro and in vivo. Molecular analyses were performed by immunoprecipitation and Western blotting.RESEARCH DESIGN AND METHODSWe performed our analysis on aortic and mesenteric segments from young and old C57BL/6 mice and on cultured endothelial cells. Resistin-induced vascular effect was evaluated in vitro and in vivo. Molecular analyses were performed by immunoprecipitation and Western blotting.Recombinant murine resistin did not induce changes in either basal vascular tone or phenylephrine-induced vascular contraction. In contrast, both in vivo and in vitro administration of resistin significantly impaired dose-dependent insulin-evoked vasodilation by reducing endothelial nitric oxide synthase (eNOS) enzymatic activity. This effect of resistin was selective for insulin vascular action, since vasodilatation induced by increasing doses of acetylcholine or nitroglycerin was not influenced by the hormone. Molecular analysis of endothelial cells further detailed resistin-induced vascular resistance by showing impairment of insulin-evoked AKT and eNOS phosphorylations after exposure to resistin. Even this latter abnormality is selective of insulin signaling since AKT/eNOS phosphorylations are normally activated during acetylcholine stimulation. More important, the resistin-induced endothelial dysfunction depends on resistin's ability to alter insulin receptor substrate (IRS)-1 tyrosine/serine phosphorylation and its consequent interaction with phosphatidylinositol 3-kinase.RESULTSRecombinant murine resistin did not induce changes in either basal vascular tone or phenylephrine-induced vascular contraction. In contrast, both in vivo and in vitro administration of resistin significantly impaired dose-dependent insulin-evoked vasodilation by reducing endothelial nitric oxide synthase (eNOS) enzymatic activity. This effect of resistin was selective for insulin vascular action, since vasodilatation induced by increasing doses of acetylcholine or nitroglycerin was not influenced by the hormone. Molecular analysis of endothelial cells further detailed resistin-induced vascular resistance by showing impairment of insulin-evoked AKT and eNOS phosphorylations after exposure to resistin. Even this latter abnormality is selective of insulin signaling since AKT/eNOS phosphorylations are normally activated during acetylcholine stimulation. More important, the resistin-induced endothelial dysfunction depends on resistin's ability to alter insulin receptor substrate (IRS)-1 tyrosine/serine phosphorylation and its consequent interaction with phosphatidylinositol 3-kinase.Our results demonstrate that resistin is able to induce a selective vascular insulin resistance-impairing endothelial IRS-1 signaling pathway that leads to eNOS activation and vasodilation.CONCLUSIONSOur results demonstrate that resistin is able to induce a selective vascular insulin resistance-impairing endothelial IRS-1 signaling pathway that leads to eNOS activation and vasodilation. |
Audience | Professional |
Author | Luca Iorio Angelo Maffei Maria Teresa Gentile Alessandro Landolfi Alba Di Pardo Giuseppe Cifelli Gennaro Marino Giovanna Antenucci Giacomo Frati Giuseppe Lembo Carmine Vecchione Alessandra Aretini |
Author_xml | – sequence: 1 givenname: Maria Teresa surname: Gentile fullname: Gentile, Maria Teresa organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy – sequence: 2 givenname: Carmine surname: Vecchione fullname: Vecchione, Carmine organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy – sequence: 3 givenname: Gennaro surname: Marino fullname: Marino, Gennaro organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy – sequence: 4 givenname: Alessandra surname: Aretini fullname: Aretini, Alessandra organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy – sequence: 5 givenname: Alba surname: Di Pardo fullname: Di Pardo, Alba organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy – sequence: 6 givenname: Giovanna surname: Antenucci fullname: Antenucci, Giovanna organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy – sequence: 7 givenname: Angelo surname: Maffei fullname: Maffei, Angelo organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy – sequence: 8 givenname: Giuseppe surname: Cifelli fullname: Cifelli, Giuseppe organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy – sequence: 9 givenname: Luca surname: Iorio fullname: Iorio, Luca organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy – sequence: 10 givenname: Alessandro surname: Landolfi fullname: Landolfi, Alessandro organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy – sequence: 11 givenname: Giacomo surname: Frati fullname: Frati, Giacomo organization: Department of Experimental Medicine and Pathology, La Sapienza University of Rome, Rome, Italy – sequence: 12 givenname: Giuseppe surname: Lembo fullname: Lembo, Giuseppe organization: Department of Angio-Cardio-Neurology, Neuromed Institute, Pozzilli, Italy, Department of Experimental Medicine and Pathology, La Sapienza University of Rome, Rome, Italy |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20181688$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18065520$$D View this record in MEDLINE/PubMed |
BookMark | eNpt0l9rUzEUAPAgE9dVH_wCUgQHinfLnya593GUOQuFgaj4FtLk3LvMNKnJvTq_vamtlo4SSEL4nUNycs7QSYgBEHpJ8AVlTF7aJZYV5lw-QSPSsKZiVH47QSOMCa2IbOQpOsv5HmMsyniGTkmNBecUj9D7T5Bd7l2YzFdr7VKezEMevAvV9c_4Hezkq87ROq97F8Nz9LTVPsOL3TpGXz5cf559rBa3N_PZ1aIygvK-0gCYMzw1FqQmmPCGWKbbli2FJqbmTBANwmLGqRQWpnXdCgq8GCrBNpKN0fk27zrFHwPkXq1cNuC9DhCHrCRmU8YlK_D1I3gfhxTK3RQlYloLWuAYVVvUaQ_KhTb2SZsOAiTtSyFbV46viBSCU9HQ4i-O-DIsrJw5GvD2IKCYHh76Tg85q_pmcWirY9ZE76EDVco4uz30r3YvHJYrsGqd3Eqn3-rfDxbwZgd0Ntq3SQfj8n9HMamJqOv9JU2KOSdo96mw2nSR2nSR2nRRsZePrHH93w4olXD-aMS7bcSd6-5-uQTKOr2EHvJ-w6ViZZLsD1uS0kQ |
CODEN | DIAEAZ |
CitedBy_id | crossref_primary_10_1016_j_cardfail_2010_05_027 crossref_primary_10_1155_2017_2712751 crossref_primary_10_1007_s12020_015_0709_4 crossref_primary_10_1038_srep22193 crossref_primary_10_1249_MSS_0b013e3181ba6dd3 crossref_primary_10_1016_j_bbrc_2009_04_074 crossref_primary_10_1111_j_1748_1716_2008_01891_x crossref_primary_10_1113_JP282728 crossref_primary_10_1016_j_clinbiochem_2013_10_021 crossref_primary_10_1007_s00421_024_05468_5 crossref_primary_10_3177_jnsv_60_52 crossref_primary_10_1074_jbc_RA118_004882 crossref_primary_10_1111_andr_12853 crossref_primary_10_1002_cbin_10595 crossref_primary_10_1016_j_bcp_2024_116245 crossref_primary_10_1111_bph_12993 crossref_primary_10_1016_j_atherosclerosis_2014_07_027 crossref_primary_10_1152_physrev_00034_2018 crossref_primary_10_1248_bpb_34_307 crossref_primary_10_1111_bph_13767 crossref_primary_10_1038_jhh_2010_22 crossref_primary_10_1155_2013_230868 crossref_primary_10_3389_fphar_2018_01226 crossref_primary_10_1007_s11906_012_0259_6 crossref_primary_10_1080_07315724_2014_933685 crossref_primary_10_1254_fpj_137_131 crossref_primary_10_1016_j_regpep_2008_07_008 crossref_primary_10_18821_0023_2149_2017_95_4_322_327 crossref_primary_10_1016_j_mam_2019_02_003 crossref_primary_10_1111_j_1476_5381_2011_01369_x crossref_primary_10_1371_journal_pone_0089745 crossref_primary_10_1016_j_bbrc_2010_02_053 crossref_primary_10_1152_ajpendo_00578_2012 crossref_primary_10_1152_ajpheart_00431_2009 crossref_primary_10_3233_JAD_181079 crossref_primary_10_1186_s12876_017_0592_y crossref_primary_10_3390_cells12081196 crossref_primary_10_1002_dmrr_907 crossref_primary_10_3389_fmed_2022_844266 crossref_primary_10_1038_hr_2008_35 crossref_primary_10_14341_omet201745_9 crossref_primary_10_1139_y2012_053 crossref_primary_10_1186_1741_7015_9_25 crossref_primary_10_1007_s00125_013_3016_8 crossref_primary_10_1007_s00441_015_2274_9 |
Cites_doi | 10.1016/S0092-8674(01)00239-2 10.1038/oby.2003.137 10.1161/01.HYP.0000082806.73530.68 10.1074/jbc.M211926200 10.1161/01.CIR.0000147825.97879.E7 10.1074/jbc.M407358200 10.1007/s00125-003-1228-z 10.1210/jc.2003-030519 10.1074/jbc.M101521200 10.1152/ajpendo.1994.267.2.E187 10.1016/j.atherosclerosis.2006.05.039 10.1152/physrev.1995.75.3.473 10.1016/S0021-9258(17)37568-3 10.1038/21218 10.1016/S0002-9149(03)00611-8 10.1146/annurev.bi.63.070194.001135 10.1111/j.1365-2265.2005.02207.x 10.1038/oby.2002.1 10.1172/JCI200421270 10.1177/153537020523000901 10.1161/01.RES.43.6.854 10.2337/diabetes.52.8.1943 10.1056/NEJM198708063170605 10.1016/S0008-6363(99)00094-2 10.1038/21224 10.2337/diabetes.50.1.159 10.1210/endo.142.7.8283 10.1016/S1043-2760(98)00110-6 10.1210/jc.2005-1653 10.2337/diabetes.48.7.1359 10.1016/j.tcm.2006.03.008 10.1172/JCI10582 10.1111/j.1365-2265.2007.02743.x 10.1161/01.CIR.0000084503.91330.49 10.1172/JCI16521 10.1172/JCI118871 10.1161/01.STR.0000038989.90931.BE 10.2337/diacare.14.3.173 10.1038/414799a 10.1172/JCI20785 10.1111/j.1365-2796.2004.01306.x 10.1046/j.1464-5491.1999.00023.x 10.1530/eje.0.1490331 10.1007/s00125-005-0060-z 10.1038/35053000 10.1074/jbc.M103702200 |
ContentType | Journal Article |
Copyright | 2008 INIST-CNRS COPYRIGHT 2008 American Diabetes Association COPYRIGHT 2008 American Diabetes Association Copyright American Diabetes Association Mar 2008 |
Copyright_xml | – notice: 2008 INIST-CNRS – notice: COPYRIGHT 2008 American Diabetes Association – notice: COPYRIGHT 2008 American Diabetes Association – notice: Copyright American Diabetes Association Mar 2008 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 8GL 3V. 7RV 7X7 7XB 88E 88I 8AF 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K9- K9. KB0 LK8 M0R M0S M1P M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U S0X 7X8 |
DOI | 10.2337/db07-0557 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: High School ProQuest Central (Corporate) Proquest Nursing & Allied Health Source Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection eLibrary Curriculum ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection ProQuest Consumer Health Database ProQuest Health & Medical Collection Medical Database ProQuest Research Library Science Database Biological Science Database Research Library (Corporate) ProQuest Nursing and Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic SIRS Editorial MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China ProQuest One Applied & Life Sciences Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Research Library ProQuest Public Health ProQuest Central Basic ProQuest Science Journals ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | CrossRef Research Library Prep MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1939-327X |
EndPage | 583 |
ExternalDocumentID | 1453078811 A176652692 18065520 20181688 10_2337_db07_0557 diabetes_57_3_577 |
Genre | Journal Article |
GroupedDBID | - 08R 0R 1AW 29F 2WC 3V. 4.4 53G 55 5GY 5RE 5RS 5VS 7RV 7X7 88E 88I 8AF 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8GL 8R4 8R5 AAQQT AAWTL AAYEP AAYJJ ABFLS ABOCM ABPTK ABUWG ACDCL ACGOD ACPRK ADACO ADBBV ADBIT AENEX AFKRA AHMBA ALMA_UNASSIGNED_HOLDINGS AZQEC BAWUL BBAFP BBNVY BCR BCU BEC BENPR BES BHPHI BKEYQ BKNYI BLC BPHCQ BVXVI C1A CS3 DIK DU5 DWQXO E3Z EBS EDB EJD EX3 F5P FRP FYUFA GICCO GJ GNUQQ GUQSH GX1 H13 HCIFZ HZ H~9 IAG IAO IEA IHR INH INR IOF IPO K-O K9- KM KQ8 L7B LK8 M0R M1P M2O M2P M2Q M5 M7P MBDVC O0- O5R O5S O9- OB3 OBH OK1 OVD P2P PADUT PCD PEA PQEST PQQKQ PQUKI PRINS PROAC PSQYO Q2X RHF RHI RPM S0X SJFOW SJN SV3 TDI WH7 WOQ WOW X7M XZ ZA5 ZY1 --- .55 .GJ .XZ 08P 0R~ 18M 354 6PF AAFWJ AAKAS AAYOK AAYXX ACGFO ADGHP ADZCM AEGXH AERZD AIAGR AIZAD ALIPV BTFSW CCPQU CITATION EMOBN HMCUK HZ~ ITC K2M M5~ N4W NAPCQ OHH PHGZM PHGZT TEORI TR2 UKHRP VVN W8F YFH YHG YOC ~KM 1CY 8F7 AFFNX AI. IQODW J5H MVM PJZUB PPXIY PQGLB VH1 XOL YQJ ZGI ZXP CGR CUY CVF ECM EIF NPM PMFND 7XB 8FK K9. PKEHL Q9U 7X8 PUEGO |
ID | FETCH-LOGICAL-c625t-aee05304cde7a101591d3aff3b6a1c85361ae6d035276de488f62e5d3a27ed973 |
IEDL.DBID | BENPR |
ISSN | 0012-1797 1939-327X |
IngestDate | Sun Aug 24 03:43:23 EDT 2025 Fri Jul 25 19:27:40 EDT 2025 Fri Jun 13 00:42:06 EDT 2025 Tue Jun 10 21:31:03 EDT 2025 Fri Jun 27 03:48:20 EDT 2025 Tue Jun 10 19:35:34 EDT 2025 Mon Jul 21 05:45:31 EDT 2025 Mon Jul 21 09:17:54 EDT 2025 Tue Jul 01 03:03:58 EDT 2025 Thu Apr 24 22:51:46 EDT 2025 Fri Jan 15 19:45:56 EST 2021 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Endocrinopathy Pancreatic hormone Vasomotricity Diabetes mellitus Insulin Vasodilation Resistin |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c625t-aee05304cde7a101591d3aff3b6a1c85361ae6d035276de488f62e5d3a27ed973 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://diabetesjournals.org/diabetes/article-pdf/57/3/577/389966/zdb00308000577.pdf |
PMID | 18065520 |
PQID | 216486234 |
PQPubID | 34443 |
PageCount | 7 |
ParticipantIDs | gale_incontextcollege_GICCO_A176652692 highwire_diabetes_diabetes_57_3_577 gale_infotracgeneralonefile_A176652692 pascalfrancis_primary_20181688 crossref_primary_10_2337_db07_0557 pubmed_primary_18065520 proquest_journals_216486234 gale_incontextgauss_8GL_A176652692 crossref_citationtrail_10_2337_db07_0557 gale_infotracacademiconefile_A176652692 proquest_miscellaneous_70343573 |
ProviderPackageCode | RHF RHI CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2008-03-01 |
PublicationDateYYYYMMDD | 2008-03-01 |
PublicationDate_xml | – month: 03 year: 2008 text: 2008-03-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Alexandria, VA |
PublicationPlace_xml | – name: Alexandria, VA – name: United States – name: New York |
PublicationTitle | Diabetes (New York, N.Y.) |
PublicationTitleAlternate | Diabetes |
PublicationYear | 2008 |
Publisher | American Diabetes Association |
Publisher_xml | – name: American Diabetes Association |
References | 2022031304032683900_R40 2022031304032683900_R11 2022031304032683900_R33 2022031304032683900_R10 2022031304032683900_R32 2022031304032683900_R31 2022031304032683900_R30 2022031304032683900_R15 2022031304032683900_R37 2022031304032683900_R14 2022031304032683900_R36 2022031304032683900_R13 2022031304032683900_R35 2022031304032683900_R12 2022031304032683900_R34 2022031304032683900_R19 2022031304032683900_R18 2022031304032683900_R17 2022031304032683900_R39 2022031304032683900_R16 2022031304032683900_R38 2022031304032683900_R6 2022031304032683900_R5 2022031304032683900_R4 2022031304032683900_R3 2022031304032683900_R9 2022031304032683900_R8 2022031304032683900_R7 2022031304032683900_R22 2022031304032683900_R44 2022031304032683900_R21 2022031304032683900_R43 2022031304032683900_R20 2022031304032683900_R42 2022031304032683900_R41 2022031304032683900_R2 2022031304032683900_R26 2022031304032683900_R48 2022031304032683900_R1 2022031304032683900_R25 2022031304032683900_R47 2022031304032683900_R24 2022031304032683900_R46 2022031304032683900_R23 2022031304032683900_R45 2022031304032683900_R29 2022031304032683900_R28 2022031304032683900_R27 Diabetes. 2010 Jan;59(1):319 |
References_xml | – ident: 2022031304032683900_R3 doi: 10.1016/S0092-8674(01)00239-2 – ident: 2022031304032683900_R21 doi: 10.1038/oby.2003.137 – ident: 2022031304032683900_R6 doi: 10.1161/01.HYP.0000082806.73530.68 – ident: 2022031304032683900_R37 doi: 10.1074/jbc.M211926200 – ident: 2022031304032683900_R32 doi: 10.1161/01.CIR.0000147825.97879.E7 – ident: 2022031304032683900_R14 doi: 10.1074/jbc.M407358200 – ident: 2022031304032683900_R8 doi: 10.1007/s00125-003-1228-z – ident: 2022031304032683900_R13 – ident: 2022031304032683900_R26 doi: 10.1210/jc.2003-030519 – ident: 2022031304032683900_R45 doi: 10.1074/jbc.M101521200 – ident: 2022031304032683900_R5 doi: 10.1152/ajpendo.1994.267.2.E187 – ident: 2022031304032683900_R31 doi: 10.1016/j.atherosclerosis.2006.05.039 – ident: 2022031304032683900_R1 doi: 10.1152/physrev.1995.75.3.473 – ident: 2022031304032683900_R44 doi: 10.1016/S0021-9258(17)37568-3 – ident: 2022031304032683900_R17 doi: 10.1038/21218 – ident: 2022031304032683900_R48 doi: 10.1016/S0002-9149(03)00611-8 – ident: 2022031304032683900_R35 doi: 10.1146/annurev.bi.63.070194.001135 – ident: 2022031304032683900_R29 doi: 10.1111/j.1365-2265.2005.02207.x – ident: 2022031304032683900_R16 doi: 10.1038/oby.2002.1 – ident: 2022031304032683900_R24 doi: 10.1172/JCI200421270 – ident: 2022031304032683900_R40 doi: 10.1177/153537020523000901 – ident: 2022031304032683900_R27 – ident: 2022031304032683900_R15 doi: 10.1161/01.RES.43.6.854 – ident: 2022031304032683900_R47 doi: 10.2337/diabetes.52.8.1943 – ident: 2022031304032683900_R4 doi: 10.1056/NEJM198708063170605 – ident: 2022031304032683900_R36 doi: 10.1016/S0008-6363(99)00094-2 – ident: 2022031304032683900_R18 doi: 10.1038/21224 – ident: 2022031304032683900_R19 doi: 10.2337/diabetes.50.1.159 – ident: 2022031304032683900_R43 doi: 10.1210/endo.142.7.8283 – ident: 2022031304032683900_R10 doi: 10.1016/S1043-2760(98)00110-6 – ident: 2022031304032683900_R30 doi: 10.1210/jc.2005-1653 – ident: 2022031304032683900_R41 doi: 10.2337/diabetes.48.7.1359 – ident: 2022031304032683900_R42 doi: 10.1016/j.tcm.2006.03.008 – ident: 2022031304032683900_R39 doi: 10.1172/JCI10582 – ident: 2022031304032683900_R28 doi: 10.1111/j.1365-2265.2007.02743.x – ident: 2022031304032683900_R7 doi: 10.1161/01.CIR.0000084503.91330.49 – ident: 2022031304032683900_R12 doi: 10.1172/JCI16521 – ident: 2022031304032683900_R33 doi: 10.1172/JCI118871 – ident: 2022031304032683900_R20 doi: 10.1161/01.STR.0000038989.90931.BE – ident: 2022031304032683900_R2 doi: 10.2337/diacare.14.3.173 – ident: 2022031304032683900_R46 doi: 10.1038/414799a – ident: 2022031304032683900_R25 doi: 10.1172/JCI20785 – ident: 2022031304032683900_R23 doi: 10.1111/j.1365-2796.2004.01306.x – ident: 2022031304032683900_R9 doi: 10.1046/j.1464-5491.1999.00023.x – ident: 2022031304032683900_R22 doi: 10.1530/eje.0.1490331 – ident: 2022031304032683900_R38 doi: 10.1007/s00125-005-0060-z – ident: 2022031304032683900_R11 doi: 10.1038/35053000 – ident: 2022031304032683900_R34 doi: 10.1074/jbc.M103702200 – reference: - Diabetes. 2010 Jan;59(1):319 |
SSID | ssj0006060 |
Score | 2.1557245 |
Snippet | Resistin Impairs Insulin-Evoked Vasodilation
Maria Teresa Gentile 1 ,
Carmine Vecchione 1 ,
Gennaro Marino 1 ,
Alessandra Aretini 1 ,
Alba Di Pardo 1 ,... OBJECTIVE—Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently... Since vascular dysfunction is a main trait of obese subjects, in the present study we evaluated the vascular impact of resistin, a recently discovered hormone... |
SourceID | proquest gale pubmed pascalfrancis crossref highwire |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 577 |
SubjectTerms | Adaptor Proteins, Signal Transducing - metabolism Adipocytes Aging Animals Aorta - drug effects Aorta - metabolism Biological and medical sciences Blood pressure Body fat Care and treatment Cells, Cultured Diabetes Diabetes mellitus Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Endothelial Cells - drug effects Endothelial Cells - metabolism Etiopathogenesis. Screening. Investigations. Target tissue resistance Glucose Health aspects Hormones Insulin - blood Insulin - metabolism Insulin - pharmacology Insulin Receptor Substrate Proteins Insulin resistance Kinases Male Medical sciences Mesenteric Arteries - drug effects Mesenteric Arteries - metabolism Mice Mice, Inbred C57BL Musculoskeletal system Nitric oxide Nitric Oxide Synthase Type III - antagonists & inhibitors Nitric Oxide Synthase Type III - metabolism Obesity Phosphatidylinositol 3-Kinases - metabolism Phosphorylation Plasma Proto-Oncogene Proteins c-akt - metabolism Research design Resistin - blood Resistin - metabolism Resistin - pharmacology Vasodilation - drug effects |
Title | Resistin Impairs Insulin-Evoked Vasodilation |
URI | http://diabetes.diabetesjournals.org/content/57/3/577.abstract https://www.ncbi.nlm.nih.gov/pubmed/18065520 https://www.proquest.com/docview/216486234 https://www.proquest.com/docview/70343573 |
Volume | 57 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9swED-NIk17mfa9wNZFbGJ7WES-HKdPiFVlMA02oTH1zXJsByFQArjd37-72glEYnuJIvXXNj77Puy7_A7gQ67Rrcq4jiptVJQXZR3JGO_SvMZJrlhSr0h9jo6Lg9P825zNfW2O9WWVnU1cGWrdKjoj30kxrsfoO8t3r64jahpFyVXfQWMN1tECl2wE619mxz9PelOM0bl7ByVJiYeTO2qhNMv4jq7ojI6RW7rjkDqz3HEFU6mktCit2rW5-HccuvJH-0_gsQ8kwz0380_hgWmewcMjnyp_Dp9PjCX9bcJD1PjzGxseurLzaPanvTA6_C1tq89dKdwLON2f_ZoeRL41QqRww7KIpKGWDnGutOEStYpNEp3Jus6qQiYKXXCRSFNoIjvlhTaopXWRGoaYlBs94dlLGDVtY15DSLvUmEtV4fdwb8hLSuhi3FJNWCmrJA3gUycfoTxvOLWvuBS4fyBRChKlIFEGsNVDrxxZxn2gbRKyIPKJhqpblDshETi-6Q-xR4yV1PYc_3hrCDyTS2tF-fX7APTRg-oWn0pJ_1YBjo2IrQbI7QHyzNF63wd8302_6A7Ab28YFxlecBjjwcroB5wSBVpRlgFsdktFeLtgRb-KA3jXf4oKTVka2Zh2aQWaYAxheRbAK7e-bkVJSXCWxhv__eVNeORqWqhO7g2MFjdL8xYDp0U1hjU-53gtp8nYq8pfCKsWVg |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dT9RAEJ8gJOqL8dsKQoOKPNjQbj-292AM4OGd3J2GgOFt3XZ3CdG0QO80_lH-j87ctoUm6BsvlyY3_djZ2fnYmf0NwKtIoVmVvvEypXMvSlLjSR-vWGRwkrM4MHNQn_EkGRxFn47j4wX405yFobLKRifOFbUqc9oj32Lo16P3HUbvz849ahpFydWmg4aVin39-xdGbNW74Qec3teM7fUPdwde3VTAy9HVn3pSUzMEP8qV5hLlMe4FKpTGhFkigxyNVxJInSiCCeWJ0ijfJmE6RhrGterxEJ97C5bQy-jhIlra6U--HLSqH6MBe-YlYIT7yS2UEQtDvqUy2hOMyQxeMYCNGWiwiak0U1Y4O8a21fi33zu3f3v34V7tuLrbVtIewIIuHsLtcZ2afwRvD3RF-qJwh6hhTi8qd2jL3L3-z_K7Vu5XWZXq1JbePYajG-HaE1gsykI_A5eiYp_LPMP7MBblKSWQ0U_KenEqs4A5sNnwR-Q1Tjm1y_ghMF4hVgpipSBWOrDekp5ZcI7riDaIyYLALgqqpsntjozA8e1-FtuEkElt1vHF613CEzmrKpF-HHWI3tREpsSvymV9igHHRkBaHcqNDuWJhRG_jvBlM_2i2XC_vIi5CPEHh7HakYx2wIwg15I0dWC5ERVR66FKtKvGgbX2X1QglBWShS5nlUCVj8LMQweeWvm6ZCUl3WPmP__vk9fgzuBwPBKj4WR_Ge7aehqq0VuBxenFTL9Ap22ardZLxYVvN706_wKTl1Gp |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEB6VIlW8oHKbltYqUHjAir0-1nlAqEobGnqAEEV9W9Z7VFUru62TIn4a_46ZrJ1gqfDWl8hSxsfOzs6xM_sNwKtEo1mVoQ0KbVSQZLkNZIhXLLE4yUUa2Smoz8FhtnuUfDpOjxfgd3sWhsoqW504VdS6UrRH3mPo16P3HSc921RFfNkefri4DKiBFCVa224aTkL2zK-fGL3V70fbONWvGRvufBvsBk2DgUCh2z8OpKHGCGGitOESZTPtRzqW1sZFJiOFhiyLpMk0QYbyTBuUdZsxkyIN40b3eYzPvQN3ecxz6hqRD-bVJRgXuNMvESMEUO5AjVgc854uaHcwJYP4lylsDUKLUkxFmrLGebKuwca_PeCpJRwuw_3GhfW3nMw9gAVTPoSlgyZJ_wjefTU1aY7SH6GuOb2q_ZEreA92rqszo_3vsq70qSvCewxHt8KzJ7BYVqV5Bj7FxyGXqsD7MCrlOaWS0WMq-mkui4h58Lblj1ANYjk1zjgXGLkQKwWxUhArPdiYkV44mI6biDaJyYJgL0qSIOX2ZgSOb_BZbBFWJjVcxxdvdAlP5KSuRf5xv0P0piGyFX6Vks15BhwbQWp1KDc7lCcOUPwmwpft9It2631-kXIR4w8OY60jGbMBMwJfy_Lcg5VWVESjkWoxWz8erM_-RVVC-SFZmmpSC1T-6Dzz2IOnTr7mrKT0e8rC5_998jos4ZoU-6PDvRW45wprqFhvFRbHVxPzAr23cbE2XSc-_LjthfkHJqVUOw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Resistin+impairs+insulin-evoked+vasodilation&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=Gentile%2C+Maria+Teresa&rft.au=Vecchione%2C+Carmine&rft.au=Marino%2C+Gennaro&rft.au=Aretini%2C+Alessandra&rft.date=2008-03-01&rft.eissn=1939-327X&rft.volume=57&rft.issue=3&rft.spage=577&rft_id=info:doi/10.2337%2Fdb07-0557&rft_id=info%3Apmid%2F18065520&rft.externalDocID=18065520 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon |